John Kapoor, the founder of Insys Therapeutics Inc., could be sentenced to several years in prison and ordered to forfeit up to $113 million for his role in a bribery and fraud scheme that contributed to the U.S. opioid crisis.
Amphora has the opportunity to completely disrupt the birth control market with a new viscous and bioadhesive contraceptive.
Abbott’s shares rose to an all-time high after the device maker beat Wall Street estimates for quarterly sales on higher demand for the company’s nutrition products and generic drugs.
Johnson & Johnson forecast 2020 profit below Wall Street estimates and said increased competition for the company’s off-patent treatments could somewhat limit growth in the top-earning pharmaceuticals unit.
Indianapolis-based Eli Lilly is adding 462 new jobs in Durham County, North Carolina over five years.
Since completing the acquisition of Shire plc in January 2019, which created one of the largest drug developers focused on rare diseases, Takeda Pharmaceutical Co. has strived to transform itself into becoming a front-runner in multiple areas including cell and gene therapies.
Eli Lilly’s senior vice president and chief financial officer Josh Smiley announced plans for the Indianapolis-based pharmaceutical company to spend from $1 billion to $5 billion each quarter during 2020 to bolster the drug manufacturer’s product pipeline.
Leading topics of the 2020 J.P. Morgan Healthcare Conference included a general lack of big deals, defining digital health, and biopharma’s diversity problem.
Novo Nordisk’s new diabetes pill Rybelsus will be covered by Express Scripts Holding Co., one of the largest U.S. pharmacy benefit managers, the Danish drugmaker said on Friday.
Fingerpaint announced a new partnership with Thrive Global aimed at educating employees through personal health and wellness content and empowering them with the tools they need to improve productivity and manage stress.